Harvard Apparatus Regenerative Technology Inc. HRGN
Set alert
2.30 USD 0.00 0.00%
As of Nov 2, 10:57 AM ET
2.30 Day range 2.45
0.96 52-week range 2.46
- YTD
- +25.00%
- 1 year
- +19.17%
- Open
- 2.45
- Prev close
- 2.30
- Mkt cap
- 46.65M
- Vol
- 700
- Avg vol
- 1.61K
- EPS
- -0.39
- P/E
- 0.00
More statistics
- Low
- 2.30
- High
- 2.45
2Y chart
Signals (109)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 2026 | 16 hours ago |
| SMA: Bullish | Oct 29, 2026 | 4 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| RSI: Overbought | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| RSI: Oversold | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 28, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
Newest 20 of 109.
Financials — quick view
HRGN Revenue — quarterly 0
HRGN Net income — quarterly -2.61M
HRGN EPS — quarterly -0.19
News
- Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic
- Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease
- Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)
- Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia
- Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
- Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
- Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
- Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
Your note
Sign in to keep a note on HRGN — it syncs with the Stock Master app.